|
Market Closed -
Nasdaq
16:00:00 2026-11-13 EST
|
5-day change | 1st Jan Change | ||
| 21.89 USD | -0.41% |
|
+1.25% | +125.21% |
| 10-28 | Replimune Group, Inc., Q2 2027 Earnings Call, Oct 28, 2026 | |
| 10-28 | Replimune Group, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2026 | CI |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Compared values
| Sector | Change | 5-day change | YTD change | 1-year change | 5-year change | Capi. | ST | MT | LT | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| REPLIMUNE GROUP, INC. | Other Biotechnology & Medical Research | -0.41% | +1.25% | +125.21% | +143.76% | -34.54% | 2.08B |  | | |
- Stock Market
- Stocks
- REPL Stock
- Charts Replimune Group, Inc.
- Comparison Chart
Select your edition
All financial news and data tailored to specific country editions
